Documentos de Académico
Documentos de Profesional
Documentos de Cultura
OUTLINE
History of Labels Regulations and Legislation Specific Drug Product Data
Vasoconstrictor Assay
History of Labels
Labels - 1970's
Lidex (fluocinonide) Gel, 0.05% - Class II steroid Precaution Section: If extensive areas are treated, the possibility exists of increased systemic absorption and suitable precautions should be taken.
Pediatric Subcommittee of the AIDAC October 29-30, 2003 ,
Labels - 1980's
TEMOVATETM (clobetasol cream and ointment), 0.05%, a Class I steroid - Approved in 1985 PRECAUTIONS: General: TEMOVATETM is a highly potent topical corticosteroid that has been shown to suppress the HPA axis at doses as low as 2 g per day. Pediatric Use: Use of TEMOVATETM Cream and Ointment in children under 12 years of age is not recommended.
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 6
Precautions Section
Precautions Section
10
General: Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal from treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.
Pediatric Subcommittee of the AIDAC October 29-30, 2003 ,
11
Patients applying a potent topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests.
Pediatric Subcommittee of the AIDAC October 29-30, 2003 ,
12
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids.
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 13
14
Safety and effectiveness in children and infants have not been established. Because of a higher ratio of skin surface area to body mass, children are at a greater risk than adults of HPA-axis-suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment.
Pediatric Subcommittee of the AIDAC October 29-30, 2003 ,
15
HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include low plasma cortisol levels to an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
16
17
1994 - Pediatric Rule 1997 - Section 111 of FDAMA 2002 Best Pharmaceuticals for Children Act
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 18
Pediatric Rule
allowed for extrapolation of adult efficacy data to pediatric patients when appropriate, plus additional safety, pk, and/or dose ranging studies in the targeted pediatric population
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 19
20
21
22
Dermatop (prednicarbate emollient cream), 0.1% a Class V steroid Approved May 1996 Pediatric Atopic Dermatitis Trial
23
59 pediatric patients enrolled 2 targeted populations - patients between 1 month and 2 years - patients between 2 and 12 years 10 patients were <2 years old 49 patients were 2 years old
Pediatric Subcommittee of the AIDAC October 29-30, 2003 ,
24
Treatment Criteria
>20% body surface area (BSA) involvement Twice daily for 21 consecutive days ACTH Stimulation Test Cosyntropin administered at baseline and day 22 Patients 15 kg received 0.25 mg IV Patients < 15 kg received 0.125 mg IV
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 25
Criteria per protocol for a normal adrenal response to ACTH stimulation at 30 and 60 minutes:
Post stimulation serum cortisol >20 g/dL If pre-stimulation serum cortisol levels > 20 g/dL, an incremental increase >6 g/dL in serum cortisol
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 26
Three patients according to the protocol criteria were suppressed: 2 patients, 1 an 18 month old, had a peak response of 5 g/dL change from baseline. 1 patient had a poststimulation cortisol value that decreased from baseline. At that time, the Agency agreed with an outside endocrinologist that since these 3 patients had a poststimulation response that was greater than 20 g/dL, although they didn't have the required incremental rise, they would not be considered suppressed. This led to the current label that reads that "none of the 59 patients showed evidence of HPA axis suppression."
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 27
Cutivate (fluticasone) Cream, 0.05% a Class V steroid Approved June 17, 1999 Pediatric Atopic Dermatitis and Psoriasis Trial
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 28
43 patients were evaluable ( all with moderate to severe atopic dermatitis) 29 patients 3 months to 2 years old 14 patients 3 years to 5 years old
29
Treatment Criteria
At least 35% BSA involvement Bid application for 3 - 4 weeks Patients up to 2 years limited to 120 grams/week Patients 3-5 years of age limited to 180 grams/week
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 30
31
33
Subject
Age/Sex
%BSA
Severity
Duration
Amt. Used
Prestim
Poststim
Prestim
Poststim
Prestim
Poststim
B201
5 yrs/M
95 (95)
22 (9)
4 weeks
561.0 grams
22.1
33.9
7.1
11.8
2.1
19.8
B202
2 yrs/M
35 (35)
17 (7)
5 weeks
176.5 grams
10.8
28.6
2.1
9.4
LTF
LTF
34
35
37
# suppressed %
Recovery of normal HPA axis function 4 patients were retested 2 weeks post- treatment and 3 of the 4 recovered normal function of the HPA axis.
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 41
Label Change for Diprolene AF Cream, 0.05% Indication - added an age restriction of 13 years and older Clinical Safety Information - Updated in the Clinical Pharmacology, Precautions: General and Pediatric Use Sections
43
# suppressed
36
29
27
17
46
Statistical Analysis in the Development of HPA Axis Suppression No statistically significant effect for Drug usage % BSA Weight Age Higher proportion of males than females (p=0.006) who developed HPA axis suppression
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 47
48
# suppressed %
30
23
14
52
Recovery of HPA Axis Function Diprosone Cream 2/10 patients were retested 1/2 (50%) recovered HPA axis function at 2 weeks
Pediatric Subcommittee of the AIDAC October 29-30, 2003 ,
54
55
57
# suppressed
None enrolled -
None enrolled -
70
80
58
59
6/11 patients were retested 4/6 (67%) recovered HPA axis function at 2 weeks
60
61
62
Lotrisone Cream
Tinea Pedis Study Tinea Cruris Study Both studies were in the adolescent population ages 12 16 years Medication was applied twice daily Study duration
4 weeks for tinea pedis 2 weeks for tinea cruris
63
64
Updated Safety Information Precautions: General, Pediatric Use, Geriatric Use and Dosage and Administration Sections
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 65
66
67
Adolescent study
24 evaluable patients 14 treated with Clobex Lotion and 10 treated with Temovate E Cream Moderate to severe atopic dermatitis BSA treated at least 20% Medication applied BID for 2 weeks 50 grams/week limit
Pediatric Subcommittee of the AIDAC October 29-30, 2003 ,
68
69
Statistical Analysis
Mean %BSA treated was higher for patients with adrenal suppression 32.8% vs. 27.7% for Clobex Lotion 35% vs. 25.3% for Temovate E Cream
70
71
Adult Study
18 evaluable patients 9 treated with Clobex Lotion and 9 treated with Temovate E Cream Moderate to Severe Atopic Dermatitis Mean BSA treated 19.3 % for Clobex Lotion and 19.4% for Temovate E Cream Medication applied BID for 2 weeks 50 gram/week limit
72
73
74
Adult Study
20 evaluable patients 10 treated with Clobex lotion and 10 treated with Temovate E Cream Moderate to Severe Plaque Psoriasis Mean BSA treated 16.2 % for Clobex Lotion and 17.9 % for Temovate E Cream Medication applied BID for 4 weeks 50 gram/week limit
75
Summary
HPA axis suppression does occur with the use of topical corticosteroids The adrenal suppression is not limited to the super potent class of topical corticosteroids The type of vehicle may contribute to the extent of absorption of the active chemical moiety The suppression appears, in most cases, to be reversible upon cessation of drug usage
Pediatric Subcommittee of the AIDAC October 29-30, 2003 , 78
FDA Experience:
Topical Corticosteroids and HPA Axis Suppression
79